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Molecular Detection of Drug Resistance (M DDR ) 
by DNA Sequencing (Version 2.0)
W hat is the advantage of M DDR?
The ability to rapidly and accurately detect drug resistance in Mycobacterium  
tuberculosis Complex (MTBC) is critical for the effective treatment o f patients suffering 
from tuberculosis (TB) and relevant interventions o f TB control programs. Efforts to treat 
patients and control the spread o f TB can be hindered by the emergence o f MTBC 
resistant to both first and second line anti-TB drugs. Additionally, the slow growth rate of 
MTBC and inherent difficulties associated with conventional drug susceptibility testing 
methods often serve as impediments to obtaining timely results. Since September 2009, 
the Laboratory Branch o f the Division o f Tuberculosis Elimination at U.S. CDC has 
offered a molecular testing service using conventional DNA sequencing for the 
identification o f drug resistance associated mutations in isolates o f MTBC. In June 2012, 
the service was expanded by incorporating pyrosequencing (PSQ) into the testing 
algorithm and by accepting nucleic acid amplification-positive (NAAT+) sputum 
sediments for testing to provide the ability for local providers and programs to potentially 
further reduce delayed diagnosis o f M DR TB. The service allows rapid identification of 
multidrug-resistant (MDR) TB through the detection o f genetic mutations associated with 
rifampin (RMP) and isoniazid (INH) resistance. In addition, when resistance to RMP is 
already known or detected in the M DDR service, genetic loci associated with resistance 
to ethambutol (EMB), pyrazinamide (PZA), and the most effective second-line drugs, 
fluoroquinolones (FQ) and the injectables amikacin (AMK), kanamycin (KAN), and 
capreomycin (CAP), are examined.




W hat is known about the genetic basis of resistance in M TBC?
The phenotypic drug resistance o f clinical isolates o f MTBC as determined by 
conventional, growth-based, drug susceptibility testing (DST) methods is explained by 
the presence o f mutations in specific genes. These mutations often consist o f only a 
single nucleotide change in the DNA sequence (i.e., point mutation). For example, >95% 
of clinical isolates that are resistant to RMP have a single point mutation in an 81-bp 
region o f the rpoB  gene known as the RMP resistance determining region (RRDR) (1). 
M utations in this region affect the protein structure o f the target so that RMP cannot 
bind; thus, conferring resistance. Similarly, 70-90% of INH-resistant isolates can be 
detected by sequencing the inhA  promoter region, the inhA  gene, and the katG  gene (1). 
INH resistance can be attributed to mutations in the inhA  promoter region which lead to 
overproduction o f the drug target and mutations within katG  which inhibit activation of 
the INH prodrug. Rapid detection o f the presence o f these mutations in rpoB, inhA, and 
katG  can indicate that the isolate is resistant to RMP or INH weeks before conventional 
DST results would typically be available.
Though the genetic basis o f resistance for some o f the first and second line anti-TB drugs 
has been identified (2,3), some resistant isolates have unexplained mechanisms of 
resistance. As a result, the interpretation o f molecular assays examining mutations 
associated with resistance must be done with a thorough understanding o f the limitations 
o f the test results. Although the presence o f many mutations indicates that a clinical 
isolate is most likely resistant to the drug o f interest; the absence o f a mutation is not 
confirmation o f drug susceptibility.
M olecular Detection of Drug Resistance (MDDR) service 
W hat technology will be used?
DNA sequencing technology was chosen as the platform for M DDR for multiple reasons. 
First, the platform is semi-automated. In addition, the assay provides rapid results with
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extensive information regarding the specific mutations. Conventional PCR and 
pyrosequencing (PSQ) will be performed on submitted sputum specimen sediments 
where initial nucleic acid amplification (NAA) testing for M TBC is positive and on 
submitted isolates o f MTBC when the RMP susceptibility results are unknown (e.g., 
testing not completed or in progress); this testing will include only genetic loci associated 
with INH and RMP resistance. W hen a mutation is detected by PSQ that indicates 
possible RMP resistance, testing will automatically reflex to conventional (i.e., Sanger) 
DNA sequencing o f the comprehensive panel (genetic loci associated with resistance to 
INH, RMP, EMB, PZA, FQ, and second-line injectable drugs). W hen an isolate of 
MTBC or NAAT+ sputum sediment is submitted with known resistance to RMP, or 
when clinical indications require a more comprehensive testing panel, PSQ will be by­
passed and the comprehensive panel testing will the performed. The testing algorithm 
used for each sample submitted will be determined by CDC based on information on the 
M DDR request form.
MDDR V2.0 Algorithm
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Sediments will be inoculated into growth medium to obtain an MTBC isolate. All 
isolates, including those isolated from sputum sediments, will also undergo conventional 
DST using the agar proportion method to determine phenotypic resistance to first- and 
second-line drugs (RMP, INH, EMB, streptomycin, ofloxacin, ciprofloxacin, KAN, CAP, 
AMK, ethionamide, and para-aminosalicylic). PZA testing will be performed by the 
MGIT 960 method.
W hat genetic loci will be sequenced as part of the M DDR service?
The PSQ panel and the comprehensive panel were designed to be able to detect resistance 
associated mutations defining M DR TB and extensively drug-resistant (XDR) TB, 
respectively. (MDRTB is defined as resistance to at least RMP and INH; XDR TB is 
defined as M DR TB plus resistance to a FQ and at least one o f the second-line anti-TB 
injectable drugs: KAN, CAP or AMK.). Specific regions (loci) associated with genes 
previously reported to confer resistance will be sequenced including “hot spots” in rpoB  
(81 bp region associated with RMP resistance), inhA promoter region and katG  
(associated with INH resistance), embB  (associated with EMB resistance), pncA  
(associated with PZA  resistance), gyrA (associated with FQ resistance), rrs (associated 
with resistance to KAN, AMK, and CAP), tlyA (associated with CAP resistance), and eis 
(promoter region associated with KAN resistance).
W hat are the performance characteristics of M DDR at CDC?
Combined sensitivity and specificity for the retrospective (254 clinical isolates) and 
prospective (80 clinical isolates) validation phases for MDDR as well as the results of 
225 clinical isolates submitted for M DDR analysis (Sept2009— Feb2011) were calculated 
using conventional drug susceptibility results (agar proportion method) as the gold 
standard. For PZA, sensitivity and specificity were calculated using MGIT PZA  results 
as the gold standard. Presence or absence o f a mutation in pncA  was used to indicate 
resistance and susceptibility by MDDR, respectively. However, the clinical significance 
o f many o f the mutations detected in pncA, with respect to prediction o f PZA resistance, 
is unknown.
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Performance characteristics of M DDR by Drug
Drug






RMP rpoB 97.1 97.4
INH inhA + katG 86.0 99.1
FQ gyrA 79.0 99.6
KAN rrs + eis 86.7 99.6
AMK rrs 90.9 98.4
CAP rrs + tlyA 55.2 91.0
EMB embB 78.8 94.3
PZA pncA 86.0 95.9
W hat are the limitations to the M DDR service?
The limitations o f the M DDR service can be attributed primarily to gaps in knowledge 
and the limit o f detection o f the assays being used. One limitation is that the clinical 
relevance o f some mutations remains unknown. M any times sequencing will identify 
mutations known to be associated with resistance to a particular drug; however, 
sometimes the association o f detected mutations with resistance will be unknown because 
the mutation is novel or there is is insufficient genetic data to definitively associate the 
mutation with resistance. An additional limitation is that not all mechanisms o f resistance 
are known. Therefore, if  no mutation is detected by the molecular assay, resistance can 
not be ruled out. Genetic analysis may miss mutations in heterogeneous samples (i.e., 
only a portion o f cells in the population being tested carry a mutation associated with 
resistance).
Used alone, M DDR and conventional DST are imperfect, yet when used in conjunction 
with one another, accuracy o f the detection o f drug resistance can be improved. 
Conventional DST results are still essential to confirm susceptibility to individual drugs. 
However, there are situations when M DDR results indicate resistance due to the presence 
o f a mutation yet the conventional DST results indicate susceptibility. For example,
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certain mutations in rpoB  are associated with RMP resistance but drug susceptibility 
testing may be falsely susceptible (4). Ongoing studies at CDC and other laboratories 
will inform our understanding o f these situations.
Use of the M DDR service by submitters 
W hat are the submission criteria for MDDR?
Isolates o f MTBC and NAAT+ positive processed sputum sediment specimens may be 
submitted by U.S. Public Health Laboratories for M DDR if  one o f the following criteria 
is met:
1) By patient history, there is a high-risk o f RMP resistance or M DR TB (including 
those previously treated for TB, a contact o f drug resistant TB, who are foreign- 
born from an area with high rates o f M DR TB)
2) Known RMP resistance (by rapid test or by culture-based DST)
3) Patients where the result o f drug resistance will predictably have a high public 
health impact (e.g., daycare workers, nurses)
4) Patient is known to have certain adverse reactions to critical anti-TB drug (e.g., 
allergy to RMP)
5) M ixed or non-viable cultures
6 ) Isolates which fail to grow in DST medium
7) Other situations considered on case by case basis
W hat sample types will be accepted?
NAAT(+) sputum sediments and isolates o f MTBC will be accepted. Isolates can be 
submitted on either solid media (e.g., LJ or M iddlebrook) or as broth cultures. When 
shipping sputum sediment or broth culture, please send 0.5— 1 ml in a screw-cap cryovial 
that has been sealed with parafilm. Do not send any samples in 50 ml conical tubes. 
Bactec460 bottles will not be accepted. Only one sample per patient should be 
submitted; however, testing o f duplicate samples will be considered on a case by case 
basis.
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M DDR does not take the place o f conventional culture and DST for MTBC. Standard of 
care testing (i.e., smear, culture, and DST) should be performed in the submitting 
laboratory when NAAT(+) sputum sediments are submitted for M DDR testing.
How do I submit a sample for the M DDR service?
Submitters should complete all portions o f the M DDR request form and submit via email 
(TBLab@cdc.gov) or FAX (404-639-5491). Once approved, CDC will send an email 
with further submission instructions. Please attach the M DDR request form to the CDC 
requisition (http://www.cdc.gov/ncidod/dvbid/misc/CDC50 34.pdf) when shipping. 
Sediments and isolates should be shipped via overnight service to CDC Monday through 
Thursday. Do not ship on Friday. Liquid samples do not need to be shipped on dry ice.
Samples should be shipped in compliance with federal regulation.
http://www.cdc.gov/ncidod/srp/specimens/shipping-packing.html (shipping information)
Shipping address:
ATTN: STAT Lab 
B. Metchock, Unit 29 
1600 Clifton Road, NE 
Atlanta, Ga. 30333 
770-488-7100
Questions regarding the use o f the A PHL’s FedEx Account for shipment should be 
addressed to APHL (tam.van@ aphl.org; kelly.wroblewski@ aphl.org) .
How will M DDR results be reported?
Reports will be issued by FAX to the submitting laboratory when the PSQ panel or the 
comprehensive panel results are available. A final report will be issued when 
conventional DST results are available. Comments regarding discordance between 
conventional DST results and MDDR, if  appropriate, will be included. The submitting 
laboratory is responsible for dissemination o f CDC reports to the TB program / clinician 
as appropriate.
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W hat if I have trouble interpreting M DDR results?
Laboratorians, TB control personnel, and clinicians can contact the CDC for help in 
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